Patents Assigned to FRESENIUS KABI USA, LLC
-
Patent number: 10188663Abstract: The invention provides a fulvestrant composition comprising not more than 2% total impurities that comprises a nonionic surfactant and/or a ricinoleate vehicle and which, optionally, is free of a non-aqueous ester solvent. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: GrantFiled: October 31, 2017Date of Patent: January 29, 2019Assignee: Fresenius Kabi USA, LLCInventor: Jabar A. Faraj
-
Publication number: 20180153838Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.Type: ApplicationFiled: September 11, 2017Publication date: June 7, 2018Applicant: Fresenius Kabi USA, LLCInventors: Arunya USAYAPANT, Basma M. IBRAHIM
-
Patent number: 9925117Abstract: A pre-filled syringe storing an anesthetic is disclosed. The pre-filled syringe includes a container configured to store a liquid anesthetic solution. The liquid anesthetic solution includes an anesthetic, water, and a solvent. The container is made of a plastic that is inert to the anesthetic. The pre-filled syringe also includes a plunger made of siliconized bromobutyl rubber that is inert to the anesthetic and a rubber stopper made of siliconized bromobutyl rubber that is inert to the anesthetic. The plunger and the rubber stopper seal the container configured to store the liquid anesthetic solution.Type: GrantFiled: May 16, 2013Date of Patent: March 27, 2018Assignee: Fresenius Kabi USA, LLCInventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
-
Publication number: 20180050046Abstract: The invention provides a fulvestrant composition comprising not more than 2% total impurities that comprises a nonionic surfactant and/or a ricinoleate vehicle and which, optionally, is free of a non-aqueous ester solvent. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: ApplicationFiled: October 31, 2017Publication date: February 22, 2018Applicant: Fresenius Kabi USA, LLCInventor: Jabar A. FARAJ
-
Patent number: 9833459Abstract: The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: GrantFiled: January 15, 2016Date of Patent: December 5, 2017Assignee: Fresenius Kabi USA, LLCInventor: Jabar A. Faraj
-
Publication number: 20170296667Abstract: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.Type: ApplicationFiled: March 30, 2017Publication date: October 19, 2017Applicant: Fresenius Kabi USA LLCInventors: John Jiang, Arunya Usayapant, David Bowman, Keith Kwok, Joel Peterson
-
Patent number: 9782376Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.Type: GrantFiled: December 1, 2016Date of Patent: October 10, 2017Assignee: Fresenius Kabi USA LLCInventors: Arunya Usayapant, Basma M. Ibrahim
-
Publication number: 20170248605Abstract: The invention provides a method for analyzing a protamine sample for the presence or amount of at least one nucleotidic impurity. The invention also provides a method for the quantitation of peptides in a sample of protamine comprising four major peptides and at least one related impurity.Type: ApplicationFiled: April 6, 2017Publication date: August 31, 2017Applicant: Fresenius Kabi USA, LLCInventors: Pearle TORRALBA, David JESCHKE, Kamlesh PATEL
-
Patent number: 9664685Abstract: The invention provides a method for analyzing a protamine sample for the presence or amount of at least one nucleotidic impurity. The invention also provides a method for the quantitation of peptides in a sample of protamine comprising four major peptides and at least one related impurity.Type: GrantFiled: October 16, 2013Date of Patent: May 30, 2017Assignee: Fresenius Kabi USA, LLCInventors: Jay Mowli, Pearle Torralba, Kamlesh Patel
-
Patent number: 9636407Abstract: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.Type: GrantFiled: December 21, 2012Date of Patent: May 2, 2017Assignee: FRESENIUS KABI USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, David Bowman, Keith Kwok, Joel Peterson
-
Publication number: 20160129014Abstract: The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Applicant: Fresenius Kabi USA, LLCInventor: Jabar A. FARAJ
-
Patent number: 9271990Abstract: The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.Type: GrantFiled: February 14, 2014Date of Patent: March 1, 2016Assignee: Fresenius Kabi USA, LLCInventor: Jabar A. Faraj
-
Publication number: 20160015641Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 0.1 to 7 milligrams mannitol.Type: ApplicationFiled: September 25, 2015Publication date: January 21, 2016Applicant: FRESENIUS KABI USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
-
Patent number: 9168239Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.Type: GrantFiled: March 13, 2015Date of Patent: October 27, 2015Assignee: Fresenius Kabi USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
-
Patent number: 9168238Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.Type: GrantFiled: March 8, 2015Date of Patent: October 27, 2015Assignee: Fresenius Kabi USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
-
Patent number: 9072655Abstract: A container storing an anesthetic is disclosed. The container is sealed by a closure and stores a liquid anesthetic solution. The anesthetic is from 0.1% to 10% by weight of the liquid anesthetic solution. The container is made of a material that is inert to the anesthetic and the closure is made of siliconized rubber or a metal. A concentration of the anesthetic in a liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in a liquid anesthetic solution before the liquid anesthetic solution is stored in the container.Type: GrantFiled: April 22, 2014Date of Patent: July 7, 2015Assignee: FRESENIUS KABI USA, LLCInventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Ci
-
Patent number: 9072656Abstract: A container storing an anesthetic is disclosed. The container is sealed by a closure and stores a liquid anesthetic solution. The anesthetic is from 0.1% to 10% by weight of the liquid anesthetic solution. The container is made of a material that is inert to the anesthetic and the closure is made of siliconized rubber or a metal. A concentration of the anesthetic in a liquid anesthetic solution stored in the container following a predetermined time period is at least 93% of a concentration of the anesthetic in a liquid anesthetic solution before the liquid anesthetic solution is stored in the container.Type: GrantFiled: April 23, 2014Date of Patent: July 7, 2015Assignee: FRESENIUS KABI USA, LLCInventors: Neil P. Desai, Andrew Yang, Sherry Xiaopei Cl
-
Publication number: 20150182484Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.Type: ApplicationFiled: March 13, 2015Publication date: July 2, 2015Applicant: FRESENIUS KABI USA, LLCInventors: Zhi-Qiang Jiang, Arunya Usayapant, George Monen
-
Publication number: 20150174246Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.Type: ApplicationFiled: March 8, 2015Publication date: June 25, 2015Applicant: FRESENIUS KABI USA, LLCInventors: Zhi-Qiang Jiang, Arunya Usayapant, George Monen
-
Patent number: 9006289Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.Type: GrantFiled: August 29, 2012Date of Patent: April 14, 2015Assignee: Fresenius Kabi USA, LLCInventors: Zhi-Qiang Jiang, Arunya Usayapant, George Monen